Introduction {#s1}
============

Exocysts are multifunctional protein scaffolds that mediate vesicle tethering during exocytosis (Luo et al., [@B29]), but also function in many other membrane trafficking pathways during endocytic recycling and transcytosis (Jafar-Nejad et al., [@B23]; Oztan et al., [@B37]), cytokinesis (Fielding et al., [@B11]; Gromley et al., [@B16]; Cascone et al., [@B5]), ciliogenesis (Zuo et al., [@B60]; Das and Guo, [@B9]), and ciliary shedding (Overgaard et al., [@B36]), cell motility (Rosse et al., [@B44]; Zuo et al., [@B61]; Spiczka and Yeaman, [@B49]), autophagy (Bodemann et al., [@B3]; Simicek et al., [@B46]), membrane nanotube formation (Hase et al., [@B17]), invadopodia formation (Sakurai-Yageta et al., [@B45]; Liu et al., [@B28]), phagocytosis (Mohammadi and Isberg, [@B32]), and bacterial invasion into host cells (Nichols and Casanova, [@B35]). Not all activities that have been attributed to exocyst complexes involve the tethering of membranes, however. Additional functions for exocyst components have been described in tumor cell survival (Chien et al., [@B7]), innate immunity signaling (Ishikawa et al., [@B22]; Simicek et al., [@B46]), and DNA repair (Torres et al., [@B53]).

In order to coordinate exocyst activities in such a diversity of events, cells must exert precise spatio-temporal regulation over exocyst recruitment to different cellular compartments and association with additional factors that execute specific functions there. A growing list of exocyst-binding proteins is emerging (Sivaram et al., [@B47]; France et al., [@B13]; Medkova et al., [@B30]; Goehring et al., [@B14]; Jin et al., [@B24]; Parrini et al., [@B38]; Morgera et al., [@B33]; Dubuke et al., [@B10]), and for many of those that have been examined, their localization and function is dependent on recruitment to exocyst complexes at those sites (Fielding et al., [@B11]; Gromley et al., [@B16]). Most "accessory proteins" do not bind the exocyst consitutively, but do so in a manner that is regulated by either phosphorylation (Chen et al., [@B6]; Stalder and Novick, [@B50]) or, more commonly, small GTPases (Chien et al., [@B7]; Rittmeyer et al., [@B42]; Sakurai-Yageta et al., [@B45]; Spiczka and Yeaman, [@B49]; Lalli, [@B26]; Bodemann et al., [@B3]; Pathak et al., [@B39]; Das et al., [@B8]).

We hypothesize that exocysts are allosterically regulated scaffolds that expose or conceal binding sites for pathway-specific factors at different times and places within cells. By electron microscopy, purified endogenous exocyst complexes from *Saccharomyces cerevisiae* resemble a collection of long rods, which consist of tightly packed helical bundles that may represent individual subunits of the complex (Heider et al., [@B19]). This structure is consistent with images generated by quick-freeze/deep-etch electron microscopy of glutaraldehyde-fixed exocyst complexes purified from rat brain extracts (Hsu et al., [@B21]). However, in the same study non-fixed exocyst complexes appeared as flowers with four to six "petals" (Hsu et al., [@B21]). This has prompted speculation that exocyst complexes may exist in different conformational states (e.g., "open" vs. "closed"; Munson and Novick, [@B34]). If exocyst activities are regulated through either conformational changes within the holocomplex or spatio-temporal control of accessory protein binding to the holocomplex, then one prediction is that different epitopes on the complex would be exposed when one exocyst is at one site engaged in one activity, but concealed on another exocyst performing a different function at a different site.

Previous studies support this prediction. For example, distinct cohorts of monoclonal antibodies were reported to label different populations of exocyst complexes associated with plasma membrane and *trans*-Golgi network of normal rat kidney cells (Yeaman et al., [@B59]). In addition, polyclonal antibodies raised against either the N- or C-terminus of Sec3 labeled plasma membranes of epithelial MDCK cells, but only N-terminal specific antibodies labeled an additional population of Sec3 associated with a perinuclear compartment (Andersen and Yeaman, [@B1]). Depending on the specific antibody used, the degree of cellular polarization and the manner in which cells were permeabilized and fixed, Sec8 has been variously localized to different plasma membrane domains (Bryant et al., [@B4]), intercellular junctions (Grindstaff et al., [@B15]; Yeaman et al., [@B58]; Andersen and Yeaman, [@B1]), centrosomes (Rogers et al., [@B43]), and endosomal populations (Folsch et al., [@B12]; Prigent et al., [@B40]; Oztan et al., [@B37]) in MDCK cells. Finally, in a number of studies individual exocyst subunits have been reported to have distinct localization patterns (Vik-Mo et al., [@B55]; Beronja et al., [@B2]; Mehta et al., [@B31]; Bryant et al., [@B4]; Bodemann et al., [@B3]). Whether these results reflect functionally distinct exocyst sub-complexes or dynamic intermediates of holocomplex assembly and disassembly is not clear, and is difficult to reconcile with recent findings that exocyst exists predominantly as a stable hetero-octamer, at least in budding yeast (Heider et al., [@B19]).

Progress toward a thorough understanding of this essential complex and its diverse functions will require careful analysis of its myriad associations and how exocyst assembly, disassembly and activity is regulated. Although results of immunolocalization studies of this complex in mammalian cells must be interpreted cautiously, we hypothesize that careful analysis with a panel of monoclonal antibodies can reveal important details about exocyst functions and regulation during its involvement in a host of cellular activities.

Material and methods {#s2}
====================

Antibodies
----------

Mouse monoclonal antibodies (mAbs) against Sec6 and Sec8 have either been described previously (Hsu et al., [@B21]; Kee et al., [@B25]; Yeaman et al., [@B59]) or were produced at the same time as previously described mAbs were. mAbs against Sec5, Exo70, and Exo84 were described previously (Vega and Hsu, [@B54]; Wang and Hsu, [@B56]; Spiczka and Yeaman, [@B49]), as was anti-CDC10 rabbit polyclonal antibody (Hsu et al., [@B20]). Rabbit polyclonal antibodies against Sec3, Sec5, Sec10, Sec15, Exo70, and Exo84 have also been described previously (Yeaman, [@B57]; Andersen and Yeaman, [@B1]). Rabbit polyclonal antibodies against Nop2 (NBP1-92192) and vimentin (NBP1-31327) were from Novus Biologica (Littleton, CO). Rabbit anti-desmoplakin-1/2 (ab14418) was from Abcam (Cambridge, MA), rabbit anti-pericentrin (PRB-432C) was from BioLegend (San Diego, CA), rabbit anti-β-tubulin (mAb 9F3) was from Cell Signaling Technology (Danvers, MA) and rabbit anti-calnexin (ADI-SPA-865) was from Enzo Life Sciences, Inc. (Farmingdale, NY). Fluorescein isothiocyanate (FITC)-goat anti-mouse, Texas Red (TR)-donkey anti-rabbit and Alexa594 goat anti-rabbit immunoglobulin (Ig)G were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). Horseradish peroxidase-conjugated goat anti-mouse and goat anti-rabbit antibodies were purchased from Promega (Madison, WI).

Cell culture
------------

Madin-Darby Canine Kidney (MDCK) strain II cells were maintained in low-glucose Dulbecco\'s modified Eagle\'s medium (LG-DMEM) with 1.8 mM Ca^2+^ containing 1 g/l sodium bicarbonate and supplemented with 10% fetal bovine serum (FBS; Cell Generation, Fort Collins, CO), penicillin, streptomycin, and gentamicin (PSG) and grown at 37°C with 5% CO~2~. For disruption of microtubules or actin, cells were incubated in medium containing either 20 μg/ml nocodazole (Sigma, St. Louis, MO) for 2 h (Reaves and Banting, [@B41]), or 2 μM cytochalasin D for 60 min (Stevenson and Begg, [@B51]).

shSec6 cells were generated by stable integration of [s]{.ul}hort [h]{.ul}airpin RNAs (shRNAs) targeting canine Sec6 (sense: 5′-GCTGCTCAGATAAGTGAAGAT-3′). shRNA was delivered via transduction with a recombinant lentiviral vector that was pseudotyped with vesicular stomatitis virus G protein. Cells were selected and maintained in medium containing 5 μg/ml puromycin. Negative controls were generated by transducing MDCK II cells with lentiviral vectors encoding a non-targeting shRNA (sense: 5′-CCAGACCTTCAAGGAATCCAT-3′) and selecting them in puromycin. Sec6 rescue cells were generated by introducing 3 wobble-base point mutations into the first three codons of the target Sec6 hairpin sequence of canine Sec6 cDNA. This cDNA was ligated into pQCXIN and delivered into shSec6 cells via retroviral transduction. Transfected cells were selected using 400 μg/ml G418 and assayed by immunofluorescence and immunoblotting for [h]{.ul}airpin [r]{.ul}esistant (hr) Sec6. shCtrl, shRalA and shRalB MDCK II cells were described previously (Hazelett et al., [@B18]).

Three-dimensional cysts of MDCK cells were generated as described (Bryant et al., [@B4]). Prior to seeding cells, a thin layer of growth factor-reduced Matrigel (BD Biosciences, Bedford, MA) was spread into 8-well Lab-Tek Chambered Coverglass slides and placed at 37°C for 10 min. Cells were trypsinized and diluted in ice-cold media to a concentration of 4 × 10^4^ cells/ml. Matrigel was diluted in ice-cold media to 4%. Matrigel solutions and cell suspensions were mixed 1:1 yielding 2 × 10^4^ cells/ml in a 2% Matrigel solution. Solutions were then added to wells of chambered coverglass slides and placed at 37°C for 4 days.

Epitope mapping
---------------

Sequences from a cDNA encoding rat Sec6 were subcloned into the pGEX-KG vector to express as GST-fusion proteins in *E. coli*. Initially, four Sec6 fragments were generated, corresponding to amino acid residues 2--125 (Sec6.1 = NT1), 126--376 (Sec6.2 = NT2), 377--597 (Sec6.3), and 586--755 (Sec6.4). Subsequently, fragments of the C-terminal half were redesigned based on structural characterization of yeast Sec6 (Songer and Munson, [@B48]) and expressed as CT1 (residues 377--487), CT2 (residues 488--625), and CT3 (residues 626--755). GST-fusion proteins were purified from bacterial lysates and serial three-fold dilutions were applied to Immobilon PVDF membrane (Millipore) and blocked with Blotto (5% nonfat dry milk, 0.5% normal goat serum, and 0.1% sodium azide in TBS) overnight at 4°C. Dot blots were incubated with primary antibodies overnight at 4°C, and then washed 5 times with TST (TBS containing 0.1% Tween-20), 10 min each. Finally, blots were incubated with HRP-labeled goat anti-mouse IgG for 45 min at room temperature and then washed as above. After 2 final washes with TBS, blots were incubated with SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) and visualized with a ChemiDoc-It™ Imaging System and quantified with Visionworks Software (UVP; Upland, CA). Segments labeled CT2a and CT2b in Figure [1](#F1){ref-type="fig"} were defined by comparing results obtained with the original Sec6.3/6.4 fragments and the redesigned Sec6 CT1/CT2/CT3 fragments. Because mAbs 2B12, 3F3, 8E6, and 8G7 bound both the Sec6.3 and CT2 fragments, whilst mAb 11A2 bound the Sec6.4 and CT2 fragments, it was deduced that these antibody groups bound different epitopes within the CT2 domain, herein labeled CT2a and CT2b.

![**Epitope mapping analysis of Sec6 monoclonal antibodies**. Antibodies produced by 24 different hybridomas were tested for binding specificity to seven recombinant Sec6 fragments, defining 6 distinct protein segments. Amino acid residues marking the boundaries of these segments in rat Sec6 are shown above each. See text for details.](fcell-04-00051-g0001){#F1}

Immunofluorescent labeling
--------------------------

Samples were fixed on ice with either 100% methanol (MeOH) or 4% paraformaldehyde (PFA) for 20 min, either prior to or following extraction with CSK buffer (1% Triton X-100, 10 mM Pipes, pH 6.8, 50 mM NaCl, 300 mM sucrose, 3 mM MgCl~2~) supplemented with protease inhibitors (1 mM pefabloc and 10 μg/ml each of aprotinin, antipain, leupeptin, and pepstatin A) for 10 min. PFA-fixed samples were then quenched with Ringer\'s saline (154 mM NaCl, 1.8 mM Ca^2+^, 7.2 mM KCl, and 10 mM HEPES, pH 7.4) containing 50 mM NH~4~Cl. After samples were blocked with 0.2% fish skin gelatin in Ringer\'s saline (blocking buffer) for 1 h, primary antibodies were diluted in blocking buffer and applied for 1 h at room temperature or overnight at 4°C with gentle rocking. After 5 washes with blocking buffer, secondary antibodies and DAPI were applied for 30 min at room temperature. Samples were washed 5 times with blocking buffer, and filters and coverslips were mounted onto slides using Elvanol-PPD. For processing MDCK cysts, all buffers were at room temperature and secondary antibodies were applied for 1 h. Images were obtained using either a Zeiss 510 scanning confocal microscope (Thornwood, NY; 63X objective) equipped with a krypton/argon laser (FITC excitation using 488 nm laser line and Texas Red excitation using 543 laser line), or with a Leica DMI 6000B microscope equipped with a *BD CARV II* spinning disk confocal imager. Stacks of confocal images were collected from several different fields using a 63X objective and a Photometrics QuantEM 512SC EM-CCD high-speed camera.

For studies examining immunofluorescence intensity at the plasma membrane, serial optical sections were merged and antibody labeling intensities at lateral plasma membranes were quantified by tracing the outlines of \~50 cells from 5 representative fields and determining mean pixel intensities using the wand tool with ImageJ software. For each sample, values were normalized by dividing the pixel intensity of Sec6 labeling by that of Sec3 labeling. One-way ANOVA with Tukey\'s post-test statistical analyses were performed for each cell type, and differences were considered significant where *p* \< 0.05.

Immunoprecipitation
-------------------

MDCK cells were washed 3 times with Ringer\'s saline on ice, and lysed in RIPA buffer (50 mM Tris-HCl pH 7.5, 1 % NP-40, 0.5% sodium deoxycholate, 150 mM NaCl, and 1 mM EDTA) containing protease inhibitors. Cell lysates were collected in 1.5 ml Eppendorf tubes and incubated on ice for 20 min at 4°C. Extracts were precleared with 5 μl of nonimmune serum and 50 μl *Staphylococcus aureus* cells (Pansorbin; Calbiochem Novabiochem, La Jolla, CA) for 1 h at 4°C. For Sec8 immunoprecipitation, mAbs 2E12, 5C3 and 10C2 were covalently cross-linked to Protein A Sepharose beads (Pharmacia LKB Nuclear, Gaithersburg, MD) with dimethyl pimelimidate (DMP), and 20 μl of immunoadsorbant was used per immunoprecipitation. For Sec6 NT or CT immunoprecipitations, combinations of either mABs that bind epitopes in NT1 or NT2 domains or those that bind epitopes in CT1, CT2, or CT3 domains were bound to Protein G Sepharose. Immunoadsorbants were incubated with pre-cleared cell extracts for 2 h at 4°C, then washed under stringent conditions and prepared for SDS-PAGE as described previously (Andersen and Yeaman, [@B1]).

Superose 6 FPLC analysis
------------------------

Confluent monolayers of MDCK cells were extracted for 10 min at 4°C in Tris-saline buffer containing 0.5% (v/v) NP-40 and protease inhibitors. Cell lysates were centrifuged at 15,000 × **g** for 10 min. The supernatant fraction was centrifuged at 100,000 × **g** for 30 min and passed through a 0.22 μm syringe filter (Millipore). Two hundred microliters of this lysate was applied to a Superose 6 HR 10/30 column and fractionated as described previously (Stewart and Nelson, [@B52]). Fractions 6--28 were separated by SDS-PAGE and proteins were electrophoretically transferred to Immobilon P membranes for immunoblotting with specific antibodies.

Gel electrophoresis and immunoblotting
--------------------------------------

Protein samples were incubated in SDS-PAGE sample buffer for 10 min at 65°C before separation on 10% SDS polyacrylamide gels. Proteins were electrophoretically transferred onto Immobilon PVDF membrane (Millipore) and blocked with Blotto (5% nonfat dry milk, 0.5% normal goat serum, and 0.1% sodium azide in TBS) overnight at 4°C. Immunoblots were incubated with primary antibodies overnight at 4°C, and then washed 5 times with TST (TBS containing 0.1% Tween-20), 10 min each. Finally, immunoblots were incubated with HRP-labeled goat anti-mouse or goat anti-rabbit antibodies for 45 min at room temperature. Immunoblots were washed as above, then twice with TBS. Immunoblots were incubated with SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific) and visualized with a ChemiDoc-It™ Imaging System and quantified with Visionworks Software (UVP; Upland, CA).

Results {#s3}
=======

Epitope mapping defines distribution of antibody binding sites on Sec6
----------------------------------------------------------------------

In the course of characterizing the mammalian exocyst complex, more than 30 monoclonal antibodies were generated against a His-tagged rSec6 fusion protein that specifically immunoblotted a single 86 kDa protein in rat brain homogenate (Hsu et al., [@B21]; Kee et al., [@B25]) and cell lines (Grindstaff et al., [@B15]; Yeaman et al., [@B59]). To conduct an informed analysis of Sec6 immunolocalization in epithelial cells, we first mapped epitopes recognized by 24 of these mAbs to one of seven recombinant Sec6 fragments, which defined six unique segments of the protein. Epitopes were distributed along the length of Sec6, and the nearly all of antibodies (23) bound a single segment (Figure [1](#F1){ref-type="fig"}). Most segments were detected by at least four mAbs, and the CT1 domain bound 11 mAbs. Intriguingly, one mAb (8A5) bound epitopes in both the CT1 and CT3 domains. That this hybridoma was monoclonal was confirmed by limiting dilution re-cloning of cells. We conclude that the epitope bound by mAb 8A5 is repeated in two segments of the Sec6 C-terminal domain.

Antibodies to different Sec6 sements label distinct subcellular structures
--------------------------------------------------------------------------

When mAbs to different Sec6 segments were used to immunolabel epithelial cells, many different subcellular structures were revealed. Antibodies to the NT1 domain labeled plasma membrane weakly, but strongly labeled Sec6 in the cytosol and nucleus (Figure [2A](#F2){ref-type="fig"}). Sec8 mAb 10C2 labeled this subunit in the nucleus in a distribution similar to that seen with Sec6 NT1 antibodies (Figure [3](#F3){ref-type="fig"}). Sec6 NT1 epitopes were also detected on centrosomes, similar to localizations previously described for other exocyst subunits (Rogers et al., [@B43]; Zuo et al., [@B60]; Andersen and Yeaman, [@B1]). However, Sec6 NT1 mAbs only bound centrosomes in cells undergoing mitosis (Figures [2A](#F2){ref-type="fig"}, [4](#F4){ref-type="fig"}). Antibodies to epitopes in the NT2 domain also labeled nuclei, but in contrast to NT1 epitopes, those in the NT2 domain were concentrated in nucleoli (Figures [2A](#F2){ref-type="fig"}, [4](#F4){ref-type="fig"}). A population of Sec3 co-localized with this nucleolar-associated Sec6 pool (Figure [3](#F3){ref-type="fig"}). NT2-specific labeling became dispersed as nucleoli dissassembled, and labeling was not detected in mitotic cells (Figure [2A](#F2){ref-type="fig"}).

![**Antibodies to different Sec6 subdomains label distinct subcellular structures. (A)** Immunofluorescent labeling of MDCK cells with antibodies to Sec6 NT1 (mAb 13F10), NT2 (mAb 16G4), CT1 (mAb 10C3), CT2a (mAb 3F3), CT2b (mAb 11A2), or CT3 (mAb 8A5) subdomains ("α-Sec6") or hybridoma supernatants that were pre-incubated with recombinant Sec6 fragments containing epitopes recognized by those antibodies ("depleted"). Additional mAbs to Sec6 NT1 (mAb 8F9), NT2 (mAb 22F5), and CT1 (mAb 4C8) subdomains produced immunolocalization patterns that were indistinguishable from those of other mAbs that bound within the same subdomain. Cells were fixed with either 4% paraformaldehyde (NT1 and CT1) or 100% methanol (NT2, CT2a, CT2b, and CT3). For NT1 and NT2 labeling, cells were extracted with 1% Triton X-100 prior to fixation, and in top and bottom panels DNA was labeled with DAPI (blue). Bars = 10 μm. **(B)** Immunoblotting of Sec6 in detergent lysates of MDCK cells. Proteins (3, 1, 0.3, or 0.1 μg) were separated by SDS-PAGE and electrophoretically transferred to Immobilon P membranes. Membranes were probed with pooled antibodies to indicated Sec6 subdomains ("α-Sec6"), or with hybridoma supernatants that were pre-incubated with recombinant Sec6 fragments containing epitopes recognized by those antibodies ("Depleted"). An immunoblot probed for β-tubulin is shown as a loading control. Protein standards indicated are β-galactosidase (116 kDa), phosphorylase b (97 kDa), bovine serum albumin (66 kDa), egg albumin (45 kDa), and carbonic anhydrase (29 kDa).](fcell-04-00051-g0002){#F2}

![**Other exocyst subunits co-localize with Sec6 at sites labeled with subdomain-specific mAbs**. Immunofluorescent labeling of MDCK cells with mouse monoclonal antibodies to Sec8 \[mAb 10C2, **(A)**, *green*\] or Sec6 \[either mAb 3F3, **(B)** top row, *green* or mAb 22F5, **(B)** bottom row, *green*\] and rabbit polyclonal antibodies to Sec15 \[Rb. 96, **(B)** top row, *red*\] or Sec3 \[Rb. 92, **(B)** bottom row, *red*\]. Cells were fixed with either 100% methanol \[**(A,B)**, top row\] or were extracted with 1% Triton X-100 prior to fixation with 4% paraformaldehyde \[**(B)**, bottom row\]. DNA was labeled with DAPI (blue). Bars = 10 μm.](fcell-04-00051-g0003){#F3}

![**Characterization of novel Sec6 localizations**. MDCK cells were fixed as described for Figure [2A](#F2){ref-type="fig"} and co-labeled with antibodies to Sec6 NT1 (mAb 13F10), NT2 (mAb 16G4), CT2a (mAb 3F3), or CT2b (mAb 11A2) (green) and antibodies to indicated proteins (red). In panels showing merged images, DNA was labeled with DAPI (blue). Bars = 5 μm.](fcell-04-00051-g0004){#F4}

In contrast to N-terminal specific antibodies, mAbs that bound epitopes within the C-terminal half of Sec6 mainly labeled membrane-associated complexes. Antibodies to Sec6 CT1 include mAb 9H5, which has previously been shown to label exocyst complexes associated with the apical junctional complex (AJC), which includes tight junctions and adherens junctions (Grindstaff et al., [@B15]; Yeaman et al., [@B58]; Figure [2A](#F2){ref-type="fig"}). This pool of Sec6 has previously been shown to co-localize with Sec8 (Grindstaff et al., [@B15]; Yeaman et al., [@B58]) and Sec10 (Lipschutz et al., [@B27]). Identical labeling patterns were observed with all of the Sec6 mAbs binding epitopes in this fragment, with the single exception of mAb 8A5. This antibody, which binds an epitope repeated in the CT3 domain, labels desmosomes but not other plasma membrane regions in non-polarized cells and polarized cells grown on Transwell filters (Andersen and Yeaman, [@B1]; Figures [2A](#F2){ref-type="fig"}, [5](#F5){ref-type="fig"}). As we reported previously, most exocyst subunits can be found at desmosomes (Andersen and Yeaman, [@B1]; also note membrane-associated pool of Sec3 in Figure [3](#F3){ref-type="fig"}).

![**Immunologically distinct pools of Sec6 are localized at AJC and desmosomes**. MDCK cells were fixed and labeled with indicated antibodies to Sec6 (green) and the desmosome component, desmoplakin (red). Note that mAb 8A5 detects a pool of Sec6 that co-localizes with desmoplakin. In contrast, mAb 9H5 detects a pool of Sec6 that does not co-localize with desmosome proteins. Bar = 10 μm.](fcell-04-00051-g0005){#F5}

Several of the mAbs that bound epitopes within the CT2a domain did not label cells that had been fixed and permeabilized under any conditions tested, but one of them (mAb 3F3) strongly labeled internal membranes that were identified as endoplasmic reticulum (ER) by co-labeling with a calnexin-specific antibody (Figures [2A](#F2){ref-type="fig"}, [4](#F4){ref-type="fig"}). A similar labeling pattern was observed with select antibodies against both Sec8 and Sec15, supporting the conclusion that mAb 3F3 binds a population of Sec6 in ER-associated exocyst complexes (Figure [3](#F3){ref-type="fig"}). Finally, mAb 11A2, which binds a distinct epitope in the CT2 segment, revealed a pool of Sec6 that was associated with a filamentous cytoplasmic network (Figure [2A](#F2){ref-type="fig"}). This network was more extensively labeled with antibodies to vimentin (Figure [4](#F4){ref-type="fig"}) than it was with probes to other cytoskeletal networks, including microtubules, actin filaments, Cdc10-positive septin filaments (Figure [6A](#F6){ref-type="fig"}) and cytokeratins (not shown). Furthermore, although some overlap was observed between 11A2 labeling and microtubules and actin, filamentous Sec6 labeling was largely refractory to pharmacological disruption of those cytoskeletal structures with nocodazole or cytochalasin D, respectively (Figure [6B](#F6){ref-type="fig"}).

![**Characterication of filamentous Sec6 mAb 11A2 labeling. (A)** MDCK cells were fixed with either 100% methanol (top and bottom rows) or 4% paraformaldehyde (middle row) and co-labeled with antibodies to Sec6 CT2b (mAb 11A2) and either β-tubulin or Cdc10 or with phalloidin. Bars = 10 μm. **(B)** MDCK cells were treated with either nocodazole or cytochalasin D, as described in Material and Methods. Cells were fixed with 100% methanol and co-labeled with antibodies to Sec6 CT2b (mAb 11A2) and β-tubulin. Panels on the right show cells that were fixed with 4% paraformaldehyde and labeled with phalloidin to demonstrate appearance of the actin cytoskeleton following treatment with drugs. Bars = 10 μm.](fcell-04-00051-g0006){#F6}

To confirm that labeling with Sec6 mAbs was specific, two strategies were employed. First, immunodepletion of hybridoma supernatants with corresponding Sec6 fragments eliminated specific immunodetection of Sec6 on immunoblots (Figure [2B](#F2){ref-type="fig"}) and greatly reduced immunofluorescent staining associated with different subcellular compartments (Figure [2A](#F2){ref-type="fig"}). This confirmed that epitopes present in recombinant Sec6 fragments bound antibodies that were responsible for immunolabeling different organelles in cells. Cross-depletion of hybridoma supernatants with Sec6 fragments that did not contain associated epitopes did not diminish immunolabeling of cells (not shown). Second, RNAi-mediated reduction of Sec6 expression by \>90% as verified by immunoblotting (Figure [7A](#F7){ref-type="fig"}) severely reduced or completely eliminated all labeling patterns observed (Figure [7B](#F7){ref-type="fig"}). This strongly supports the conclusion that Sec6 is the sole protein detected by all of the mAbs in cells. Finally, expression of a hairpin-resistant Sec6 cDNA (Figure [7A](#F7){ref-type="fig"}) restored immunolabeling of all of the observed compartments (Figure [7B](#F7){ref-type="fig"}), confirming not only that Sec6 is the protein recognized by all of the mAbs on diverse structures, but also that this diversity in labeling is not caused by alternatively spliced Sec6 variants localizing to distinct subcellular sites.

![**Sec6 knockdown eliminates, and re-expression restores labeling with all Sec6 mAbs in MDCK cells. (A)** Sec6 knockdown and rescue. MDCK cells were transduced with recombinant lentiviral vectors carrying either non-targeting shRNA (shCtrl) or shRNA targeting Sec6 (shSec6). Immunoblot analysis confirmed that Sec6 protein expression was reduced in shSec6 cells by \> 90% when normalized to loading control (β-tubulin). Rescue cell lines were established by transduction of shSec6 cells with recombinant retroviral vectors carrying hairpin-resistant Sec6 cDNA. Immunoblot analysis confirmed that Sec6 protein expression was restored to nearly identical levels as those in shCtrl cells. **(B)** Control (shCtrl), Sec6 knockdown (shSec6), and Sec6 rescue MDCK cells were processed for immunofluorescent labeling with antibodies to indicated Sec6 subdomains, as described in Figure [2](#F2){ref-type="fig"}. Bar = 10 μm.](fcell-04-00051-g0007){#F7}

Sec6 epitopes are differentially exposed or concealed during epithelial polarization
------------------------------------------------------------------------------------

We next asked whether Sec6 epitopes were static, or whether they became exposed or concealed at different subcellular sites as cells underwent dynamic changes, as during morphogenesis of a three-dimensional cyst. We therefore compared localization profiles of epitopes bound by a subset of Sec6 mAbs in non-polarized and 3-D cysts of MDCK cells. When antibodies to epitopes in the C-terminal half of Sec6 were used, 2 patterns were observed. First, epitopes in the CT2b and CT3 segments appeared to redistribute during polarity development. In non-polarized and Transwell-cultured (2-D) polarized cells, mAb 8A5 labeled Sec6 in a discontinuous, punctate pattern characteristic of desmosomes, while mAb 11A2 labeled Sec6 on cytoskeletal filaments (Andersen and Yeaman, [@B1]; Figure [8A](#F8){ref-type="fig"}). In contrast, both antibodies revealed Sec6 in a uniform distribution along the basolateral plasma membrane of fully polarized cells in 3-D Matrigel cultures. In addition, mAb 11A2 detected Sec6 beneath the lumenal apical plasma membrane (Figure [8A](#F8){ref-type="fig"}). We note that a population of Sec6 remains associated with cytoplasmic filaments in 3-D cysts, but this pool is observed only when maximum intensity projections of stacked optical sections through the entire cyst are generated (not shown).

![**Sec6 epitopes redistribute during epithelial polarization. (A)** MDCK cells were cultured as sub-confluent colonies on collagen-coated glass coverslips (non-polarized) or seeded in Matrigel and grown for 4 days (polarized). Cultures were fixed in 100% methanol and labeled with indicated anti-Sec6 mAbs (green). Polarized cultures were co-labeled with DAPI (blue). Bar = 20 μm. **(B)** MDCK cells were seeded in Matrigel and grown for 4 days. Cultures were either fixed in 100% methanol (left) or pre-extracted with 1% Triton X-100 before methanol fixation (right), and labeled with indicated antibodies (green) and DAPI (blue). Bar = 20 μm.](fcell-04-00051-g0008){#F8}

A second pattern was observed with antibodies to Sec6 CT1. Epitopes within this protein segment became concealed as cells developed polarity. For example, immunolabeling with mAb 9H5 was readily detected along lateral membranes of non-polarized cells (Figure [8A](#F8){ref-type="fig"}) and this became restricted to the AJC as cells acquired 2-D polarity when grown on Transwell filters (Grindstaff et al., [@B15]; Yeaman et al., [@B58]). However, specific Sec6 labeling was undetectable in fully polarized cells grown in Matrigel (Figure [8A](#F8){ref-type="fig"}). Importantly, Sec6 is still present at AJC in fully polarized cells, because its binding partner Sec8 was readily detected there and an AJC-associated pool of Sec6 was revealed when cells were gently extracted with non-ionic detergent prior to fixation (Figure [8B](#F8){ref-type="fig"}). However, the CT1 domain becomes masked at this site as cells undergo cystogenesis.

Sec6 epitope accessibility is impacted by RalA activity
-------------------------------------------------------

We hypothesize that Ral GTPases regulate exocyst activities by facilitating association and/or dissociation of additional proteins with the holocomplex scaffold. Ral-mediated assembly or disassembly of exocyst super-complexes is expected to involve structural changes that render Sec6 epitopes more or less accessible to specific mAbs. To test this prediction, we compared binding of antibodies to the Sec6 CT1 subdomain in cells in which expression of either RalA or RalB had been suppressed. This analysis revealed that exposure of Sec6 CT1 epitopes at the plasma membrane was significantly decreased when expression of RalA, but not RalB, was reduced (Figure [9A](#F9){ref-type="fig"}). Loss of peripheral Sec6 CT1 labeling in cells lacking RalA was not due to inefficient recruitment of exocyst complexes to the plasma membrane, because peripheral Sec3 labeling was similar in control, shRalA and shRalB cells (Figure [9A](#F9){ref-type="fig"}). Furthermore, expression levels of Sec3, Sec6 and Sec8, and their assembly into exocyst complexes was unaffected by suppressing either RalA or RalB expression (Figure [9B](#F9){ref-type="fig"}). Collectively, these results support the conclusion that exocyst *conformation*, rather than expression, assembly or recruitment of the complex to the plasma membrane is regulated by RalA activity.

![**RalA regulates plasma membrane exocyst configuration**. **(A)** Accessibility of Sec6 CT1 epitopes is reduced when RalA, but not RalB, expression is suppressed. *(Top)* MDCK cells stably expressing a non-specific [s]{.ul}hort [h]{.ul}airpin RNA (shCtrl), or a hairpin specific for either RalA (shRalA) or RalB (shRalB), were fixed and labeled with a cocktail of mouse monoclonal antibodies to Sec6 domain CT1 (mAbs 4C8, 9E9, 9H5, and 15C2). Cells were co-labeled with rabbit polyclonal antisera against Sec3. Bound antibodies were revealed by indirect immunofluorescence, following labeling with FITC-anti-mouse and Texas Red-anti-rabbit antibodies. *(Bottom)* Antibody labeling intensities at the plasma membrane were quantified as described in Material and Methods. Note that Sec6CT labeling, which is primarily concentrated at the lateral plasma membrane of control cells, is diminished upon RalA, but not RalB reduction. This likely reflects differences in Sec6 conformation, rather than exocyst localization, because plasma membrane Sec3 labeling is not changed following either knockdown. Bar = 20 micron, ^\*\*^*p* \< 0.05. **(B)** Levels of Sec3/6/8 complex are not altered following suppression of either RalA or RalB expression. RIPA extracts of MDCK shCtrl, shRalA, or shRalB cells were immunoprecipitated with anti-Sec8-bound protein A sepharose. Equal fractions of input lysates and immunoprecipitates were resolved by SDS-PAGE and immunoblotted with rabbit anti-Sec3, mouse anti-Sec8(8F12) or mouse anti-Sec6(10D11) antibodies. An immunoblot probed for β-tubulin is shown as a loading control.](fcell-04-00051-g0009){#F9}

Epitope accessibility is correlated with stability of Sec6 interactions with other exocyst subunits
---------------------------------------------------------------------------------------------------

A possible explanation for why different Sec6 epitopes are either exposed or concealed in cells is that Sec6 exists in different complexes, and that spatially regulated associations with other proteins either masks or reveals epitopes in different parts of the cell or at different stages of polarity development. Importantly, epithelial cells do not accumulate a significant pool of free, monomeric Sec6. Quantitative immunoprecipiation of Sec8 recovers nearly all of the Sec6 in cell extracts (Figure [10A](#F10){ref-type="fig"}). This is consistent with a recent report that Sec6 and Sec8 form a stable subunit pair in budding yeast (Heider et al., [@B19]). Gel filtration chromatography of MDCK cell lysates shows that this Sec6/8 complex is always associated with high molecular weight assemblies (Figure [10B](#F10){ref-type="fig"}). Therefore, the diversity of immunolabeling patterns observed likely reflects heterogeneity within multiple populations of large protein assemblies containing Sec6.

![**Sec6 is quantitatively associated with Sec8 in high molecular weight complexes in MDCK cells**. **(A)** All endogenous Sec6 is bound to Sec8. MDCK RIPA extracts were immunoprecipitated 4 times with anti-Sec8-bound protein A sepharose. Input lysate represents 10% of starting material. Depleted lysate ("spent") represents 50% of the final post-immunoprecipitation supernatant. Samples were resolved by SDS-PAGE and immunoblotted with anti-Sec8(8F12) and anti-Sec6(10D11) antibodies. **(B)** Detergent extracts of polarized MDCK cells were fractionated by Superose 6 FPLC as described in Experimental Procedures. Fractions 9--27 were divided into equal aliquots, separated by SDS-PAGE, and transferred to Immobilon P membranes. Membranes were probed with anti-Sec8(8F12) and anti-Sec6(10D11) antibodies. Elution peaks of globular protein standards with known molecular weights were also determined: thyroglobulin, Mr = 669,000 (fraction 16); apoferritin, Mr = 443,000 (fraction 19); catalase, Mr = 232,000 (fraction 22); bovine serum albumin, Mr = 66,000 (fraction 25).](fcell-04-00051-g0010){#F10}

It is possible that Sec6 epitopes are differentially accessible because exocyst holocomplexes undergo context-specific conformational changes or shifts in inter-molecular interactions that impact Sec6, such that individual subdomains are either exposed or concealed. To test whether compartment-specific exposure of different epitopes was correlated with differential stability of interactions between Sec6 and other subunits, Sec6 was immunoprecipitated with cocktails of mAbs that bind epitopes in either the N-terminal or C-terminal halves of the protein, and the relative amounts of other exocyst subunits that co-precipitated was measured (Figure [11](#F11){ref-type="fig"}). mAbs to Sec6NT co-precipitated more Sec5, Sec10, Sec15, Exo70, and Exo84 than did those to Sec6CT. mAbs to Sec6CT, by contrast, co-precipitated more Sec3 and Sec8 than did those to Sec6NT. These results suggest that exocyst complexes may undergo structural transitions that conceal Sec6NT but expose Sec6CT when complexes are membrane-bound, and expose Sec6NT but conceal Sec6CT when complexes are cytosolic or nuclear.

![**Antibodies to different Sec6 domains differentially co-precipitate other exocyst subunits**. Cocktails of antibodies specific for epitopes in either the Sec6 N-terminus (8F9, 10D11, 13F10, 8A11, 1F5, 7C6, 16G4, and 22F) or C-terminus (9E9, 9H5, 10C3, 2B12, 3F3, 8E6, 11A2, and 8A5) were used to immunoprecipitate exocyst complexes from MDCK lysates. Precipitates were resolved by SDS-PAGE and immunoblotted with antibodies to either Sec6 or indicated exocyst subunits. Amounts of each subunit that were recovered were normalized to amounts of Sec6 recovered in each immunoprecipitate, and are expressed as a fraction of the total immunoprecipitated by both Sec6 NT and CT antibody cocktails. Bars represent means of three independent experiments, and error bars represent standard deviations.](fcell-04-00051-g0011){#F11}

Discussion {#s4}
==========

Previous studies of exocyst localization in mammalian epithelial cells have revealed complexes at AJC (Grindstaff et al., [@B15]; Yeaman et al., [@B58]) and desmosomes (Andersen and Yeaman, [@B1]) on basolateral plasma membranes, developing apical plasma membranes (Bryant et al., [@B4]), *trans*-Golgi network (Yeaman et al., [@B59]), recycling endosomes (Folsch et al., [@B12]; Prigent et al., [@B40]; Oztan et al., [@B37]), primary cilia (Rogers et al., [@B43]), and centrosomes (Rogers et al., [@B43]; Andersen and Yeaman, [@B1]). Discrepancies in reported localizations may reflect differences in fixation and permeabilization procedures, specific antibodies used in the study, extent of cellular polarization, growth conditions of cells, existence of exocyst sub-complexes associated with different organelles and the possibility that exocyst complexes may exist in different conformational states. In this study, we have focused on a single exocyst subunit (Sec6), carefully mapped epitopes bound by more than 20 distinct mAbs and used them to probe subdomain accessibility in exocyst complexes associated with different cellular compartments.

A major finding of this work is that epitopes mapping to different segments of Sec6 are exposed or concealed in a spatially controlled fashion in epithelial cells. Sec6 is an obligate binding partner of Sec8, and is entirely associated with large multi-protein assemblies in MDCK cells. Nevertheless, anti-Sec6 mAbs detect epitopes on different parts of this protein at different subcellular localizations. Of equal importance, no single epitope is exposed at all of these sites. This suggests that the majority of Sec6 epitopes are concealed at most sites, and that only a small subset of epitopes are exposed and this occurs in a site-specific manner. Therefore, Sec6 epitopes and the mAbs that bind them define exocyst complexes associated with one, or a small subset of cellular compartments, where they are presumably engaged in only one activity.

We also note that discrete Sec6 epitopes may appear, disappear or redistribute as cells grow and differentiate. For example, antibodies to the NT1 domain label centrosomes, but only when cells are undergoing mitosis. In contrast, antibodies to the NT2 domain label nucleoli of interphase cells, but do not detect Sec6 anywhere in mitotic cells. Epitopes in the C-terminal domain appear to redistribute during epithelial cell polarity development. The CT2b segment is accessible for mAb 11A2 binding to a pool of Sec6 associated with vimentin filaments in non-polarized cells, and no plasma membrane labeling with this antibody is observed under these conditions. However, the same antibody reveals Sec6 associated with apical and basolateral domains of fully polarized cells. Similarly, the CT3 segment is accessible for mAb 8A5 binding to a pool of Sec6 associated with desmosomes in non-polarized cells and 2-D polarized cells on Transwells (Andersen and Yeaman, [@B1]). However, this antibody labels Sec6 in a continuous and uniform distribution along the basolateral plasma membrane of fully polarized cells grown in Matrigel. Antibodies to the CT1 domain detect Sec6 at newly forming adhesive junctions and mark a complex that becomes restricted to the AJC in polarized cells grown on Transwell filters (Grindstaff et al., [@B15]; Yeaman et al., [@B58]), but do not specifically label Sec6 in fully polarized 3-D cysts. We acknowledge that care must be taken to distinguish between physical redistribution of exocyst complexes and changes in conformation and/or molecular associations that reveal or conceal epitopes at a given site, because both are likely to accompany epithelial polarity development. Because gentle pre-extraction with non-ionic detergent exposes Sec6 CT1 epitopes at the AJC of MDCK cysts, we conclude that either intramolecular interactions within the exocyst holocomplex or associations with accessory proteins mask these epitopes in fully polarized cells. Such molecular rearrangements are likely to be regulated, at least in part, by RalA, because suppressing expression of this GTPase significantly diminished binding of CT1-specific mAbs to plasma membranes without affecting the expression, assembly or recruitment of exocyst complexes to this site.

We anticipate that a thorough analysis of epitope accessibility of each subunit will reveal important details about exocyst structure, function and regulation during its involvement in many different cellular processes. A complete understanding of these functions will require comprehensive identification of accessory proteins with which exocyst holocomplexes interact at different sites. We have shown that Sec6 epitopes, and the mAbs that bind them, define exocyst complexes associated with one (or a small subset of) cellular compartments. As such, the library of Sec6 mAbs is likely to be an important resource for the study of different cohorts of exocyst complexes engaged in different cellular processes.
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